Literature DB >> 11014643

CD8+ T cells are capable of rejecting pancreatic islet xenografts.

S Yi1, X Feng, W Hawthorne, A Patel, S Walters, P J O'Connell.   

Abstract

BACKGROUND: In this study, the capacity of CD8+ T cells to act as a potential effector mechanism in pancreatic xenograft rejection was examined.
METHODS: The fate of pancreatic islet xenografts was studied in mice deficient in MHC class II molecules and CD4+ T cells. Fetal pig pancreas (FPP) or Wistar rat islets (RI) were transplanted into nondiabetic or streptozotocin-induced diabetic I-A knock-out (CII K/O) mice.
RESULTS: CII K/O mice were capable of rejecting both RI and FPP grafts. RI graft survival was not prolonged compared with wild type C57BL/6 controls. However, FPP grafts did survive longer in CII K/O recipients than in C57BL/J6 mice. Both RI and FPP graft rejection were CD8+ T-cell phenomena in CII K/O mice, as anti-CD8 monoclonal antibody prolonged graft survival, there were increased CD8+ T cells in the grafts and spleens of CII K/O recipients, and cell-mediated cytotoxicity was a CD8+ T-cell phenomenon associated with activation of the perforin/granzyme B system. By contrast, RI and FPP graft rejection was a CD4+ T cell-dependent phenomenon in wild type C57BL/6 mice with graft survival prolonged by anti-CD4 monoclonal antibody. There were increased numbers of CD4+ T cells, and cell-mediated cytotoxicity was a CD4+ T-cell phenomenon associated with activation of the Fas/FasL lytic pathway.
CONCLUSIONS: The results demonstrate that, in the absence of CD4+ T cells, CD8+ T cells were capable of rejecting both rat and pig pancreatic islet xenografts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014643     DOI: 10.1097/00007890-200009270-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  CD4+ /CD8+ T-cell ratio correlates with the graft fate in pig-to-non-human primate islet xenotransplantation.

Authors:  Hyunwoo Chung; Hyun-Je Kim; Jung-Sik Kim; Il-Hee Yoon; Byoung-Hoon Min; Jun-Seop Shin; Jong-Min Kim; Won-Woo Lee; Chung-Gyu Park
Journal:  Xenotransplantation       Date:  2019-10-23       Impact factor: 3.907

Review 2.  Responses against complex antigens in various models of CD4 T-cell deficiency: surprises from an anti-CD4 antibody transgenic mouse.

Authors:  Yifan Zhan; Lorena E Brown; Georgia Deliyannis; Shirley Seah; Odilia L Wijburg; Jason Price; Richard A Strugnell; Phillip J O'Connell; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Pancreatic islet xenotransplantation: barriers and prospects.

Authors:  Gina R Rayat; Ronald G Gill
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

Review 4.  Cellular Immune Responses in Islet Xenograft Rejection.

Authors:  Min Hu; Wayne J Hawthorne; Shounan Yi; Philip J O'Connell
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

5.  A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection.

Authors:  Ping Wang; Mehmet V Yigit; Chongzhao Ran; Alana Ross; Lingling Wei; Guangping Dai; Zdravka Medarova; Anna Moore
Journal:  Diabetes       Date:  2012-08-24       Impact factor: 9.461

6.  Survival of free and encapsulated human and rat islet xenografts transplanted into the mouse bone marrow.

Authors:  Raphael P H Meier; Jörg D Seebach; Philippe Morel; Redouan Mahou; Sophie Borot; Laurianne Giovannoni; Geraldine Parnaud; Elisa Montanari; Domenico Bosco; Christine Wandrey; Thierry Berney; Leo H Bühler; Yannick D Muller
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

7.  HLA-G1+ Expression in GGTA1KO Pigs Suppresses Human and Monkey Anti-Pig T, B and NK Cell Responses.

Authors:  Joseph Sushil Rao; Nora Hosny; Ramesh Kumbha; Raza Ali Naqvi; Amar Singh; Zachary Swanson; Heather Levy; Anders W Matson; Magie Steinhoff; Nicole Forneris; Eric Walters; Bernhard J Hering; Christopher Burlak
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.